ERBB2 and neoplasm: While targeted therapies, such as HER2 and VEGF inhibitors, have improved clinical outcomes, challenges like antigen heterogeneity, immune evasion, and immunosuppressive tumor microenvironments continue to limit their efficacy [3–8].